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Background: Heart failure (HF) is one of the most debilitating chronic illnesses. The prevalence is expected to
increase due to aging population. The current study aimed to examine the management of heart failure with
preserved ejection fraction (HFpEF) including drug use pattern, direct medical cost and humanistic outcome in a
local public hospital in Hong Kong.
Methods: The current study adopted the retrospective observational study design. Subjects were recruited from
the Heart Failure Registry of the Prince of Wales Hospital in Hong Kong between 2006 and 2008 and completed
the Minnesota Living with Heart Failure Questionnaire (MLHFQ) at 3 designated time-points conferred eligibility.
Patients with significant valvular disorder were excluded. Each patient’s medical record was reviewed for 12 months
after the date of admission. Heart failure related admissions, clinic visits, cardiovascular drugs, laboratory tests and
diagnostic tests were documented. Costs and MLHFQ scores in patients with or without hypertension, diabetes and
renal impairment were compared.
Results: A total of 73 HFpEF patients were included. It was found that loop diuretics (93.1%, 78.1%) was the most
frequently used agent for HFpEF management in both in-patient and out-patient settings. The mean 1-year direct
medical cost was USD$ 19969 (1 US $ = 7.8 HK$), with in-patient ward care contributing to the largest proportion
(72.2%) of the total cost. Patients with diabetes or renal impairment were associated with a higher cost of HFpEF
management. Significant difference was found in the renal impairment group (median cost: USD$ 24604.2 versus
USD$ 12706.8 in no impairment group, p = 0.023). The MLHFQ scores of the subjects improved significantly during
the study period (p < 0.0005).
Conclusions: The cost of management of HFpEF was enormous and further increased in the presence of
comorbidities.
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Heart failure (HF) is one of the most debilitating chronic
illnesses in Hong Kong, especially in the elderly. With
an overall incidence of 0.7 per 1000 population in 1997
[1], the number of cases of heart failure hospitalizations
has been tripled over the past 10 years [2]. In 2009, heart
failure was the cause of death of 794 patients in Hong
Kong [3]. Heart failure with preserved ejection fraction* Correspondence: vivianlee@cuhk.edu.hk
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unless otherwise stated.(HFpEF), a sub-division of heart failure, constitutes 40-
50% of heart failure cases [4,5]. When compared to heart
failure with reduced ejection fraction (HFrEF), HFpEF
has a slightly lower mortality [6] but similar hospital re-
admission rate and decline in functional status [5,7].
Nevertheless, studies investigating into the cost and drug
use pattern of HFpEF management remain limited. In
United Kingdom, the estimated direct cost for the man-
agement of HF increased from 1.2% of total National
Health Service (NHS) expenditure in 1990–01 to 1.83%
in 1995, equivalent to GBP£ 716 million [8]. The esti-
mated cost increased to 1.91% of the NHS expenditureThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ade, with 69% of the cost attributed to hospitalization
[9]. In Sweden, the estimated annual treatment cost for
HF including costs of institutional care, outpatient care,
surgery and medications, constituted 2% of the Swedish
healthcare budget [10]. In the United States, The esti-
mated direct and indirect costs of HF in 2010 were US $
24.7 billion and $ 9.7 billion respectively [11].
Given that HF has an age-related prevalence [6], it can
be anticipated that the disease will pose an increasing fi-
nancial burden to Hong Kong in view of the aging popu-
lation. In addition, the advancement in management of
acute cardiovascular disease shifts the mortality pattern
to HF. The American Heart Association projects a 200%
increase in annual medical cost of HF over 2010–2013
[11]. Hence, the current study aims to investigate the
HFpEF management in Hong Kong with the focus of the
direct medial cost, drug use pattern and humanistic out-
come of HFpEF management.
Methods
A retrospective non-randomized case review design was
adopted in this study. All study subjects were recruited
from the Heart Failure Registry of the Prince of Wales
Hospital (PWH), the major acute hospital in the New
Territories East Cluster (NTEC) in Hong Kong. Their
medical records were retrieved from the Clinical
Management System (CMS) for the evaluation of the
direct medical cost, drug use pattern and humanistic
outcome of HFpEF management during the first year
after entering the registry. The presence of comorbidi-
ties, including hypertension, diabetes mellitus and renal
impairment (defined as serum creatinine > 200 umol/L
on admission), and other baseline parameters were also
recorded. The protocol of this study was approved by
the Joint CUHK-NTEC Clinical Research Ethics Committee
in October 2011. Patients with (1) signs and symptoms
typical of HF, (2) with normal or only mildly reduced
left ventricular ejection fraction (LVEF > 40%) and (3)
relevant structural heart disease and/or diastolic dys-
function, diagnosed of HFpEF according to the diag-
nostic criteria of Heart Failure and Echocardiography
Associations of the European Society of Cardiology were
included. They were in the Heart Failure registry of
PWH within the period of 1st January, 2006 to 31st
December, 2008, and complete the Minnesota Living
with Heart Failure Questionnaire (MLHFQ) at baseline,
3 month and 12 month follow-up visits. Patients with
valvular diseases of moderate, severe or unknown severity
were excluded.
The usage of all cardiovascular medications during the
study period was recorded. Medications under consider-
ation included Angiotensin Converting Enzyme Inhibi-
tors (ACEIs), Angiotensin Receptor Blockers (ARBs),beta-blockers, Calcium Channel Blockers (CCBs), diuretics,
aldosterone antagonists, digoxin, antiplatelets, anticoagulants,
anti-arrhythmics, nitrates, vasodilators, lipid-lowering agents
and potassium supplements. The prevalence of use among
study subjects was investigated to reflect the drug use pattern
for HFpEF management in PWH in Hong Kong. The direct
medical costs for the management of HFpEF were evaluated
from the perspective of the Hong Kong Hospital Authority.
The total sum consisted of spending in HF-related hospitaliza-
tions, outpatient clinic visits and Accident and Emergency De-
partment (AED) admissions. All admissions or consultations
in which HF was a principle diagnosis or part of the focus of
management were included. The costs of all services, medica-
tions and tests were estimated with reference to the Hong
Kong Government Gazette 2003 [12] and Hong Kong Hos-
pital Authority Drug Formulary 2006 [13]. The direct
medical costs were analyzed to reveal any statistically
significant differences between subjects with or without
hypertension, diabetes mellitus or renal impairment.
The MLHFQ, a 21-item HF-specific questionnaire, was
adopted to evaluate the quality of life of the study subjects.
All subjects had completed the Chinese version of the
questionnaire at baseline, 3-month and 12-month. A 6-
point scale from 0–5 was used in the questionnaire, with 0
representing minimal impact and 5 representing most sig-
nificant impact of HF on their life during the past 4 weeks.
The overall score was a sum of the scores of the 21 ques-
tions. The physical domain score and emotional domain
score were also calculated. Higher scores indicate poorer
quality of life [14].
The prevalence of use of each drug was expressed as
the percentage of patients using the drug, while the dir-
ect medical cost for the management of HFpEF, MLHFQ
scores and other baseline values were presented in mean
± standard deviation and median with interquartile range
and range (min-max). Wilcoxon Signed Rank Test was
performed to test for statistical significance of the differ-
ences in MLHFQ scores at 3-month and 12-month with
respect to the baseline. For comparison of the direct
medical costs and MLHFQ scores between different co-
morbidity subgroups, Mann–Whitney Test was adopted.
Non-parametric tests were preferred in view of the small
sample sizes and the presence of outliers in various cohorts.
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS version 16.0, SPSS
Inc.). Differences were considered statistically significant
when the p-value is <0.05.
Ethical approval
The study was approved by the Ethics Committee,
CUHK-New Territories East Cluster, Hospital Authority,
Hong Kong. (CREC Ref. No: CRE-2011.457). The current
protocol was in compliance with the Declaration of
Helsinki.
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114 patients in the Heart Failure Registry of PWH were
screened for study eligibility. 41 subjects were excluded
as they did not meet the inclusion criteria of the study
or their medical records were incomplete. A total of 73
HFpEF patients were recruited into this study. Their
demographic characteristics and baseline parameters of
the subjects were summarized in Table 1. The majority
of the subjects were female (69.8%), with an average age of
76.2 years old on admission and average LVEF of 64.3%.
Among the three comorbidities of interest, hypertension
(76.7%) was the most common, followed by diabetes
(46.6%) and renal impairment (16.4%). 22 and 10 patients
were comorbid with 2 and 3 of the diseases respectively.
The mean length of hospital stay was 23.4 days, with an
average of 2.2 admissions per person and a readmission
rate of 52.1%. When stratified by the presence of comor-
bidity, the renal impairment group was found to have the
longest duration of hospital day (35.0 ± 32.9 days), highest
number of admissions (mean: 2.5 ± 1.0 admission) and
readmission rate (83.3%) followed by diabetes and hyper-
tension patients. The most commonly used class of medi-
cations was diuretics, with a usage rate of 94.5% and
80.8% under in-patient and outpatient settings re-
spectively. ACEIs (69.9%, 65.8%), antiplatelets (57.5%,
60.3%), beta-blockers (56.2%, 58.9%) and CCBs dihydro-
pyridine (54.8%, 57.5%) were also used in over half of the
study subjects under both settings.
The 1-year direct medical costs incurred by the man-
agement of HFpEF in the study subjects. The mean and
median total costs for HFpEF management were USD
$19969 and USD$15178.8 per patient respectively (1 US
$ = 7.8 HK$). In-patient care constituted the largest part
of expenditure among all categories and contributed to
91.7% of the total spending in HFpEF management,
followed by outpatient care and A&E admission. In-
patient ward care was the major cost driver within the
in-patient category, comprising of 72.2% of the total dir-
ect medical costs. The mean and median 1-year direct
medical costs per patient for the management of HFpEF
in different comorbidity cohorts. Subjects who were co-
morbid with renal impairment were associated with the
highest spendings in HFpEF management, with a mean
and median total cost of USD$ 31645.2 and USD
$24604.2 respectively. The cost incurred by subjects with
diabetes came second, while subjects with hypertension
were associated with the least cost for HFpEF manage-
ment. In general, the cost of care in the presence of co-
morbidity was higher than that of the overall study
subjects.
In the renal impairment group, the median costs of in-
patient (p < 0.0005) and out-patient laboratory tests (p =
0.043), overall in-patient cost (p = 0.027), overall out-
patient cost (p = 0.019) and total cost (p = 0.023) weresignificantly higher than those in the control group. For
the diabetes group, the in-paitent and out-patient costs
for medications (p = 0.009; p < 0.0005) and laboratory tests
(p = 0.001; p < 0.0005), and the overall out-patient costs
(p < 0.0005) were significantly higher than the non-diabetes
mellitus control. The costs of hypertenison group were
higher than its control, but none of the cost items reached
statistical significance.
Progressive improvements in the total scores, physical
domain and emotional domain were observed through-
out the 1-year period. When compared to the baseline
median scores, both the 3-month and 12-month total
scores and physical domain scores improved significantly
(p < 0.0005 for all). The emotional domain score also im-
proved significantly at 12-month follow-up when compared
to the baseline (p < 0.0005). However, when comparing the
scores between the comorbidity cohorts and controls, no
statistically significant differences was detected between
subjects with any one of the comorbidities and the control
groups, with only the renal impairment group showing
a significantly worse MLHFQ total scores at baseline
(p = 0.046) (Table 2).
Discussion
The demographics of the subjects in this study resem-
bled those in previous controlled trials, population-based
and registry-based studies conducted locally or overseas
[15-17]. The majority of our patients were female, which
constituted up to 70% of the study population. The sub-
jects were also at advanced age in general, with a mean
age of 76 on admission. This, together with existing stud-
ies, suggested that female sex and advanced age are preva-
lence factors of HFpEF. For the presence of comorbidities
at baseline, 77% of the study subjects had a history of
hypertension, followed by 47% for diabetes and 16.4% for
renal impairment. The proportions matched well with
those reported in the ADHERE database [15]. Similar drug
use pattern was observed in previous overseas studies by
Yancy et al. and Smith et al. in which the frequent use of
diuretics, ACEIs and beta-blockers was documented
[5,15]. Due to a lack of large randomized trials, the use
of medications in DHF is largely guided by inconclu-
sive trial results or expert opinions [14,18-20]. Con-
trol of blood pressure, heart rate and blood volume, and
prevention of myocardial ischemia were recommended by
ACC/AHA and HFSA guidelines [21,22], which were ob-
served locally.
The 1-year direct medical cost of HFpEF management
differed among subjects with different comorbidities.
The cost involved was the highest in renally impaired
subjects and lowest in those with hypertension. When
compared with the corresponding control group, statisti-
cally significant differences were shown in a number of
cost categories in diabetes and renal impairment groups,
Table 1 Demographic characteristics of study subjects




Age on admission (n, %)
Mean ± SD 76.2 ± 10.3
Aged 30-54 4 5.5%
Aged 55-64 4 5.5%
Aged 65-74 16 21.9%
Aged 75-84 37 50.7%
85 or above 12 16.4%





Ejection fraction on admission
Mean ± SD 64.3 ± 8.9%
NYHA class on admission (n, %)
Class I – II 10 13.7%
Class III 35 47.9%




Diabetes mellitus# 34 46.6%
Renal impairment$ 12 16.4%
Comorbid with 2 of the above 22 30.1%
Comorbid with 3 of the above 10 13.7%
Coronary artery disease 25 34.2%
Atrial fibrillation 17 23.3%
Blood pressure (n = 72)
• Systolic BP (mean ± SD) 155.9 ± 35.1 mmHg
• Diastolic BP (mean ± SD) 78.4 ± 19.0 mmHg
• ≥140/90 mmHg (n, %) 51 70.8%
• Comorbid with HTN (n = 55), ≥ 140/90 mmHg (n, %) 39 70.9%
• Comorbid with DM (n = 33), ≥ 130/80 mmHg (n, %) 28 84.4%
Blood glucose
HbA1c (n = 32)
Mean ± SD 6.7 ± 1.3%
>6.5% (n, %) 14 43.8%
Comorbid with DM (n = 25), > 6.5% (n, %) 14 56.0%
Fasting blood glucose (n = 32)
Mean ± SD 7.2 ± 3.3 mmol/L
≥7 mmol/L 10 31.3%
Comorbid with DM (n = 16), ≥ 7 mmol/L (n, %) 9 56.3%
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Table 1 Demographic characteristics of study subjects (Continued)
Lipid panel
LDL (n = 42, mean ± SD) 2.2 ± 1.0 mmol/L
HDL (n = 42, mean ± SD) 1.4 ± 0.6 mmol/L
Triglyceride (n = 43, mean ± SD) 1.4 ± 0.6 mmol/L
Total cholesterol (n = 45, mean ± SD) 4.2 ± 1.3 mmol/L
Serum creatinine (n = 73)
Mean ± SD 142.0 ± 100.7 umol/L
>200 umol/L$$ (n, %) 12 16.4%
Mean ± SD of subjects with sCr > 200 umol/L 330.7 ± 111.2 umol/L
#According to physician’s diagnosis.
$Defined as baseline serum creatinine > 200 umol/L.
$$Regarded as clinically significant renal dysfunction.
Leung et al. BMC Cardiovascular Disorders  (2015) 15:12 Page 5 of 7but not the hypertension group. Hypertension, diabetes
and renal impairment are diseases associated with a poorer
prognosis in HFpEF [23-25]. The presence of these comor-
bidities therefore gave rise to extra HFpEF management
costs [26]. MacDonald et al. for instance, showed that in a
group of HFpEF patients from the CHARM programme,
the rate of HF-related hospitalization was significantly
higher in the diabetic group than the non-diabetic groupTable 2 Minnesota living with heart failure questionnaire sco
by the presence of comorbidity
Hypertension
Yes N
n = 56 n
Total scores
Baseline
Median (IQR) 31 (17.25) 27
Follow-up after 3 months
Median (IQR) 21 (15.5) 30
Follow-up after 12 months
Median (IQR) 12.5 (12.25) 15
Physical domain
Baseline
Median (IQR) 18 (7.25) 18
Follow-up after 3 months
Median (IQR) 11 (9.5) 12
Follow-up after 12 months
Median (IQR) 7 (6.5) 9
Emotional domain
Baseline
Median (IQR) 5 (5) 5
Follow-up after 3 months
Median (IQR) 5 (4) 8
Follow-up after 12 months
Median (IQR) 3 (5) 5[27]. Krumholz et al. also revealed a significantly longer
duration of hospitalization and higher in-patient cost in
patients developing deteriorated renal condition than
those who did not [28]. An increase in the duration of
hospital stay certainly increases the costs of in-patient
care. Being the major cost driver in our study, this in-
creased the total direct medical cost in these comorbidity
cohorts. Apart from the increased in-patient ward careres at baseline, 3-month follow-up and 12-month follow-up
Diabetes mellitus Renal impairment
o Yes No Yes No
= 17 n = 34 n = 39 n = 12 n = 61
(15) 32 (13.75) 27 (19) 34(12.5) 28(18)
(25) 21 (14) 24 (18.5) 22(9.5) 23(21)
(12) 12 (14.25) 15 (11) 12.5(10.5) 14(13)
(8) 18.5 (4.75) 17 (10) 20(5.25) 18(8)
(13) 9 (8.5) 12 (12) 9.5(5) 11(10)
(5) 7 (8.25) 8 (6.5) 8(6.5) 7(8)
(8) 6 (5.75) 5 (5.5) 7.5(4.75) 5(6)
(10) 5 (4.75) 5 (6) 5(4.25) 5(6)
(4) 2 (5) 5 (4) 4(4.5) 4(4)
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performed with increased complexity of illness.
Given that in-patient care accounts for a major portion
of the cost of HFpEF [29,30], measures to reduce LOS and
readmission rate can potentially achieve cost-saving. Liter-
atures reported that implementation of multidisciplinary
HF management programme improved outcomes, reduced
hospitalization and lowered the cost in HFrEF [31-33]. The
intervention generally focused on optimizing drug therapy,
enhancing patients’ understanding on disease and drugs,
and improving compliance on medications and lifestyle
(e.g. salt restriction). The abovementioned local HF man-
agement programme was implemented in Pamela Youde
Netheresole Eastern Hospital in 2001–2003, comprising a
team of physicians, registered nurses, physiotherapists, oc-
cupational therapists and dietitians [34]. The programme
was found to significantly reduce hospitalization, decrease
the total number of bed day and achieve an average saving
of USD$1453.8 per patient over a 6-month period.
For the humanistic outcome, it was found that the total,
physical and emotional MLHFQ scores were reduced with
statistical significance after 1 year, indicating an improve-
ment in the quality of life of subjects during the course of
HFpEF management. The MLHFQ developers commen-
ted a 5-point improvement in the total score as clinically
significant [35]. Hence, the MLHFQ score potentially
serves as a tool to assess the benefits and risks of a treat-
ment [36-38]. In our study, the subjects on average
showed 6.39 and 14.97 points of MLHFQ score improve-
ments at 3-month and 12-month follow-up respectively.
As the Chinese version of MLHFQ was previously vali-
dated in a Taiwan study [14], the improvement in scores
was believed to reflect the effectiveness of the current in-
terventions in maintaining the quality of life of the study
subjects.
There were several limitations in the present study.
Firstly, the sample size was small. The 73 subjects re-
cruited may not be representative of the majority of HFpEF
patients, although the well-matched demographics and
baseline parameters provided some evidence of credibility.
Secondly, our sample was drawn from the NTEC. The re-
sults may not truly reflect the HFpEF management in patients
in Hong Kong due to variations in practices and management
approaches across clusters. Thirdly, the retrospective design
of our study relied on well-documented medical records.
Investigations or treatments not properly documented in-
troduced errors to cost estimation. Fourthly, the cost esti-
mation of healthcare services was based on the Hong
Kong Government Gazette 2003. The costs were assumed
to be applicable to the study period in 2006–2008 as no
update on healthcare charges was available, but the effect
of inflation was not taken into account. Last but not least,
the cost-of-illness was not limited to the direct medical
cost from the perspective of a healthcare institution.Long-term care costs, indirect medical costs and intan-
gible costs were not included in our study. Further studies
should be directed to a more holistic approach, preferably
with cost-effectiveness evaluation on the current HFpEF
treatments. This will provide more evidence-based sup-
port for local practice, given that no international consen-
sus has been reached regarding HFpEF management.
Conclusion
The present study evaluated the management of HFpEF
patients. Loop diuretics, ACEIs, beta-blockers, dihydro-
pyridine CCBs and aspirin were the most frequently pre-
scribed medications. The mean 1-year direct medical
cost was estimated to be USD$19969 per patient, with
in-patient hospitalization being the major cost driver.
Comorbid state with hypertension, diabetes or renal im-
pairment increased the cost of care and the increments
reached statistical significance for diabetes and renal
impairment. Humanistic outcome showed promising
improvement in quality of life with the local HFpEF man-
agement approach. In view of the improvement in the
prognosis of HFrEF due to advances in evidence-based
therapies yet little progress in those of HFpEF, the latter
may become the predominant form of clinical HF in the
near future, especially with the aging population in Hong
Kong. The present study provided information on the
local practice and the substantial economic burden in-
curred by HFpEF. It conveyed the need to unify every ef-
fort to improve HFpEF management, and to reduce the
associated healthcare expenditure by rational resource al-
location and development of cost-saving strategies.
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